Developer docs
API playgroundTry for free, no card

Search company profiles

Breath Diagnostics

Full company profile

uuid000464f

Namestring
Breath Diagnostics
Legal namestring
Breath Diagnostics Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Breath Diagnostics Inc. is a privately held, development-stage medical technology company founded in 2015 and headquartered in Louisville, Kentucky. The company is developing the OneBreath platform, a non-invasive in vitro diagnostic that captures and quantifies volatile organic compounds (VOCs) from a single exhaled breath to detect lung cancer, assess pre-operative pneumonia risk, and screen for other respiratory diseases such as idiopathic pulmonary fibrosis and COVID-19.

The OneBreath platform is built on a patented silicon microreactor that uses aminooxy chemistry to selectively and covalently capture carbonyl VOCs from exhaled breath, converting them into stable cationic adducts for analysis by ultra-high-performance liquid chromatography coupled with mass spectrometry (UHPLC-MS). A single 30-second breath sample is processed in under 10 minutes, with reported analytical performance of greater than 10^6 dynamic range, pptv-level sensitivity, R² greater than 0.99, and clinical performance of 94% sensitivity and 85% specificity for lung cancer detection across 800+ trial patients. The platform received FDA Breakthrough Device Designation in February 2026 for pre-operative pneumonia risk assessment and is reportedly the first LC-MS-based molecular breath test to receive this designation. Multiple global patents protect the underlying microreactor chemistry, aminooxy capture reagents, and methods for cancer detection via breath carbonyl compounds.

The company is pre-revenue and pre-FDA approval, with a planned commercialization pathway that begins with a CLIA laboratory developed test before pursuing full FDA IVD clearance. The intended go-to-market focuses initially on pulmonology practices and cancer centers leveraging clinical validation data and key opinion leader relationships, with subsequent expansion to primary care, pharmacies, and community health centers. Revenue streams are expected to include per-test fees from CLIA laboratory services, eventual commercial IVD product sales, and potential licensing of the platform's core chemistry to applications beyond lung cancer. The company has raised approximately $7.7 million in prior capital and is currently conducting a Regulation CF crowdfunding campaign of up to $3 million at a $32.1 million pre-money valuation.

Short descriptiontext

Breath Diagnostics is a Louisville, Kentucky-based medical technology company developing the OneBreath platform, a non-invasive breath diagnostic using patented microreactor chemistry and UHPLC-MS to detect lung cancer, assess pneumonia risk, and screen for respiratory diseases from a single exhaled breath.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLouisville, United States
HQ citystring
Louisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
breath cancer diagnostics, non-invasive screening, volatile organic compound detection, mass spectrometry analysis, lung cancer detection
Industry2 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Molecular Cancer Diagnostics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1OneBreath™ Diagnostic Tests
TypeOne Time License
Description

The company plans to generate revenue through sale of OneBreath diagnostic tests, initially through CLIA laboratory services and subsequently as a commercial IVD product following FDA approval. Medicare reimbursement for lung cancer screening has already been established, creating a clear path to revenue.

breathdiagnostics.com
2Platform Technology Licensing
TypeLicensing Royalties
Description

The company notes potential applications beyond lung cancer for pneumonia, COPD, tuberculosis, and other respiratory diseases, which may create licensing or partnership revenue opportunities.

breathdiagnostics.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1Diagnostic test pricing (commercial)
ModelOtherBilling cadencePay-as-you-go
Notes

Pricing not publicly disclosed. Medicare reimbursement pathways for lung cancer screening are established. Investment offering: Regulation CF up to US$3 million at US$3.00 per share with pre-money valuation of approximately US$32.1 million.

breathdiagnostics.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Breath Diagnostics develops the OneBreath™ diagnostic platform, a non-invasive in vitro diagnostic that captures and analyzes volatile organic compounds (VOCs) from a single exhaled breath to detect lung cancer and other respiratory diseases. The platform uses a patented silicon microreactor with aminooxy chemistry to derivatize carbonyl VOCs into stable cationic adducts, followed by ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) analysis, achieving 94% sensitivity and 85% specificity across 800+ patients in clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 94% sensitivity and 85% specificity for lung cancer detection in clinical trials with over 800 patients
+5 more records
Product overview1 text field

Breath Diagnostics offers OneBreath™, a single unified non-invasive diagnostic platform that analyzes exhaled breath for disease detection. The platform uses patented microreactor chemistry to capture and derivatize volatile organic compounds (VOCs), which are then quantified using UHPLC-MS analysis. Originally developed for lung cancer screening, the technology has demonstrated clinical validity for detecting multiple conditions including pneumonia, idiopathic pulmonary fibrosis (IPF), and COVID-19. The platform delivers results in under 10 minutes from a single 30-second breath collection, offering significant advantages over traditional GC-MS methods that require 15-30 minutes of sampling and up to an hour of analysis.

Product and service1 record
1OneBreath™ Diagnostic Platform
CategoryCancer diagnostic device / molecular in vitro diagnostic
Description

A non-invasive in vitro diagnostic platform that analyzes exhaled volatile organic compounds (VOCs) from a single breath to detect lung cancer and other respiratory diseases (pneumonia risk, IPF, COVID-19). The platform uses proprietary microreactor derivatization technology combined with UHPLC-MS to deliver 94% sensitivity and 85% specificity in lung cancer detection across 800+ patients in clinical trials, with results in under 10 minutes from a 30-second breath collection.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-01
Description

Breath Diagnostics installed an advanced mass spectrometry system from Waters Corp in its laboratory in late 2025. The new system enhances detection sensitivity, data quality, and reproducibility for breath analysis, strengthening the company's analytical capabilities for the OneBreath platform.

Strategic tierMinorTypeOthers
Description

Life Science Intelligence, a medtech research firm, recognized Breath Diagnostics in its 2025 Emerging Innovators Report for its non-invasive OneBreath lung cancer breath test, placing the company among over 500 innovators from 36 countries.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Several company founders (Xiao-An Fu, Michael Nantz, Victor van Berkel) are affiliated with the University of Louisville. Dr. van Berkel serves as Chief of Thoracic Surgery at UofL Health and leads clinical trials through the Brown Cancer Center. This academic-clinical partnership has driven technology development and clinical validation.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-based breath biopsy company developing non-invasive breath tests for early cancer detection (including lung cancer) and other diseases using VOC analysis. Closely comparable in target indication, breath-based technology approach, and clinical stage.

TypeDirect peer
Description

Pioneer in breath-based diagnostic testing for lung cancer and other diseases using proprietary breath collection and analysis methods. Directly comparable as a breath diagnostics company focused on respiratory and oncologic indications.

TypeEmerging player
Description

Early-stage developer of breath-based diagnostic tests for lung cancer and respiratory diseases, focused on VOC biomarker analysis. Comparable as a smaller-scale breath diagnostics player targeting similar clinical applications.

TypeEmerging player
Description

Digital health company developing breath-based disease detection technology using AI and sensor arrays. Comparable in the breath diagnostics category, though using different underlying sensor/AI approach versus Breath Diagnostics' LC-MS chemistry.

TypeBroad incumbent
Description

Major medtech incumbent with a broad respiratory diagnostics and monitoring portfolio (spirometry, pulmonary function testing). Comparable as an established respiratory diagnostics provider that OneBreath would compete against or partner with.

TypeBroad incumbent
Description

Global leader in mass spectrometry and analytical instruments used in clinical diagnostics and life sciences research. Comparable both as a potential MS instrument supplier to Breath Diagnostics and as a broad incumbent in the IVD/substance manufacturing space.

TypeOthers
Description

Mass spectrometry and UHPLC instrument manufacturer and existing technology partner to Breath Diagnostics (installed advanced MS system at Breath Diagnostics' lab in late 2025). Comparable as an enabling technology supplier for the OneBreath platform.

TypeBroad incumbent
Description

Major analytical instrument manufacturer including mass spectrometry and chromatography systems used in clinical diagnostics and research. Comparable as a potential instrument partner/competitor and broad incumbent in lab analytical instruments.

TypeBroad incumbent
Description

Major women's health and diagnostics company with growing respiratory and molecular diagnostics portfolio (including COVID-19 and pneumonia testing). Comparable as a broad incumbent in diagnostic test commercialization targeting pulmonology and infectious disease.

TypeOthers
Description

Major academic medical center operating one of the largest lung cancer screening programs in the U.S. and home to Director Jeff Rich. Comparable as a key clinical reference site and potential adoption partner for OneBreath in pulmonology and thoracic surgery.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Breath Diagnostics

Molecular Cancer Diagnosticsbreathdiagnostics.com

Breath Diagnostics is a Louisville, Kentucky-based medical technology company developing the OneBreath platform, a non-invasive breath diagnostic using patented microreactor chemistry and UHPLC-MS to detect lung cancer, assess pneumonia risk, and screen for respiratory diseases from a single exhaled breath.

What Breath Diagnostics does

Breath Diagnostics Inc. is a privately held, development-stage medical technology company founded in 2015 and headquartered in Louisville, Kentucky. The company is developing the OneBreath platform, a non-invasive in vitro diagnostic that captures and quantifies volatile organic compounds (VOCs) from a single exhaled breath to detect lung cancer, assess pre-operative pneumonia risk, and screen for other respiratory diseases such as idiopathic pulmonary fibrosis and COVID-19.

The OneBreath platform is built on a patented silicon microreactor that uses aminooxy chemistry to selectively and covalently capture carbonyl VOCs from exhaled breath, converting them into stable cationic adducts for analysis by ultra-high-performance liquid chromatography coupled with mass spectrometry (UHPLC-MS). A single 30-second breath sample is processed in under 10 minutes, with reported analytical performance of greater than 10^6 dynamic range, pptv-level sensitivity, R² greater than 0.99, and clinical performance of 94% sensitivity and 85% specificity for lung cancer detection across 800+ trial patients. The platform received FDA Breakthrough Device Designation in February 2026 for pre-operative pneumonia risk assessment and is reportedly the first LC-MS-based molecular breath test to receive this designation. Multiple global patents protect the underlying microreactor chemistry, aminooxy capture reagents, and methods for cancer detection via breath carbonyl compounds.

The company is pre-revenue and pre-FDA approval, with a planned commercialization pathway that begins with a CLIA laboratory developed test before pursuing full FDA IVD clearance. The intended go-to-market focuses initially on pulmonology practices and cancer centers leveraging clinical validation data and key opinion leader relationships, with subsequent expansion to primary care, pharmacies, and community health centers. Revenue streams are expected to include per-test fees from CLIA laboratory services, eventual commercial IVD product sales, and potential licensing of the platform's core chemistry to applications beyond lung cancer. The company has raised approximately $7.7 million in prior capital and is currently conducting a Regulation CF crowdfunding campaign of up to $3 million at a $32.1 million pre-money valuation.

Breath Diagnostics firmographics

Firmographics
Name
Breath Diagnostics
Legal name
Breath Diagnostics Inc.
Website
https://breathdiagnostics.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Breath Diagnostics is a Louisville, Kentucky-based medical technology company developing the OneBreath platform, a non-invasive breath diagnostic using patented microreactor chemistry and UHPLC-MS to detect lung cancer, assess pneumonia risk, and screen for respiratory diseases from a single exhaled breath.
Ownership category
akta.pro rank

Breath Diagnostics industry classification

Industry
Product category
Molecular Cancer Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAAALAC
Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels)

Keywords

  • Breath cancer diagnostics
  • Non-invasive screening
  • Volatile organic compound detection
  • Mass spectrometry analysis
  • Lung cancer detection

Where Breath Diagnostics is headquartered

Location

Headquarters

HQ city
Louisville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Breath Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Infrastructure, Personnel, Operations, Marketing or Sales

Revenue model

  1. OneBreath™ Diagnostic Tests: The company plans to generate revenue through sale of OneBreath diagnostic tests, initially through CLIA laboratory services and subsequently as a commercial IVD product following FDA approval. Medicare reimbursement for lung cancer screening has already been established, creating a clear path to revenue.
  2. Platform Technology Licensing: The company notes potential applications beyond lung cancer for pneumonia, COPD, tuberculosis, and other respiratory diseases, which may create licensing or partnership revenue opportunities.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goDiagnostic test pricing (commercial)

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Breath Diagnostics product offering

Product offering

Core offering

Breath Diagnostics develops the OneBreath™ diagnostic platform, a non-invasive in vitro diagnostic that captures and analyzes volatile organic compounds (VOCs) from a single exhaled breath to detect lung cancer and other respiratory diseases. The platform uses a patented silicon microreactor with aminooxy chemistry to derivatize carbonyl VOCs into stable cationic adducts, followed by ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) analysis, achieving 94% sensitivity and 85% specificity across 800+ patients in clinical trials.

Product overview

Breath Diagnostics offers OneBreath™, a single unified non-invasive diagnostic platform that analyzes exhaled breath for disease detection. The platform uses patented microreactor chemistry to capture and derivatize volatile organic compounds (VOCs), which are then quantified using UHPLC-MS analysis. Originally developed for lung cancer screening, the technology has demonstrated clinical validity for detecting multiple conditions including pneumonia, idiopathic pulmonary fibrosis (IPF), and COVID-19. The platform delivers results in under 10 minutes from a single 30-second breath collection, offering significant advantages over traditional GC-MS methods that require 15-30 minutes of sampling and up to an hour of analysis.

Differentiator

Problem solved

Functional benefit

Products and services

  • OneBreath™ Diagnostic Platform A non-invasive in vitro diagnostic platform that analyzes exhaled volatile organic compounds (VOCs) from a single breath to detect lung cancer and other respiratory diseases (pneumonia risk, IPF, COVID-19). The platform uses proprietary microreactor derivatization technology combined with UHPLC-MS to deliver 94% sensitivity and 85% specificity in lung cancer detection across 800+ patients in clinical trials, with results in under 10 minutes from a 30-second breath collection.

Quantifiable outcome

  • 94% sensitivity and 85% specificity for lung cancer detection in clinical trials with over 800 patients
  • +5 more outcomes

Companies that use Breath Diagnostics

Customer profile

Segments4 records

Ideal customer profiles3 records

Breath Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Breath Diagnostics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Waters CorporationcoreTechnology or Integration · 1 December 2025Breath Diagnostics installed an advanced mass spectrometry system from Waters Corp in its laboratory in late 2025. The new system enhances detection sensitivity, data quality, and reproducibility for breath analysis, strengthening the company's analytical capabilities for the OneBreath platform.
  • Life Science IntelligenceminorOthersLife Science Intelligence, a medtech research firm, recognized Breath Diagnostics in its 2025 Emerging Innovators Report for its non-invasive OneBreath lung cancer breath test, placing the company among over 500 innovators from 36 countries.
  • University of Louisville / UofL HealthcoreStrategic or Co-development PartnerSeveral company founders (Xiao-An Fu, Michael Nantz, Victor van Berkel) are affiliated with the University of Louisville. Dr. van Berkel serves as Chief of Thoracic Surgery at UofL Health and leads clinical trials through the Brown Cancer Center. This academic-clinical partnership has driven technology development and clinical validation.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Breath Diagnostics competitors and assessment

Company assessment

Direct peers

  • Owlstone Medical: UK-based breath biopsy company developing non-invasive breath tests for early cancer detection (including lung cancer) and other diseases using VOC analysis. Closely comparable in target indication, breath-based technology approach, and clinical stage.
  • Menssana Research: Pioneer in breath-based diagnostic testing for lung cancer and other diseases using proprietary breath collection and analysis methods. Directly comparable as a breath diagnostics company focused on respiratory and oncologic indications.

Emerging players

  • Breathtec Biomedical: Early-stage developer of breath-based diagnostic tests for lung cancer and respiratory diseases, focused on VOC biomarker analysis. Comparable as a smaller-scale breath diagnostics player targeting similar clinical applications.
  • Noze (formerly ScentAware): Digital health company developing breath-based disease detection technology using AI and sensor arrays. Comparable in the breath diagnostics category, though using different underlying sensor/AI approach versus Breath Diagnostics' LC-MS chemistry.

Broad incumbents

  • Philips Respiratory: Major medtech incumbent with a broad respiratory diagnostics and monitoring portfolio (spirometry, pulmonary function testing). Comparable as an established respiratory diagnostics provider that OneBreath would compete against or partner with.
  • Thermo Fisher Scientific: Global leader in mass spectrometry and analytical instruments used in clinical diagnostics and life sciences research. Comparable both as a potential MS instrument supplier to Breath Diagnostics and as a broad incumbent in the IVD/substance manufacturing space.
  • Agilent Technologies: Major analytical instrument manufacturer including mass spectrometry and chromatography systems used in clinical diagnostics and research. Comparable as a potential instrument partner/competitor and broad incumbent in lab analytical instruments.
  • Hologic: Major women's health and diagnostics company with growing respiratory and molecular diagnostics portfolio (including COVID-19 and pneumonia testing). Comparable as a broad incumbent in diagnostic test commercialization targeting pulmonology and infectious disease.

Others

  • Waters Corporation: Mass spectrometry and UHPLC instrument manufacturer and existing technology partner to Breath Diagnostics (installed advanced MS system at Breath Diagnostics' lab in late 2025). Comparable as an enabling technology supplier for the OneBreath platform.
  • Cleveland Clinic (Lung Cancer Screening Program): Major academic medical center operating one of the largest lung cancer screening programs in the U.S. and home to Director Jeff Rich. Comparable as a key clinical reference site and potential adoption partner for OneBreath in pulmonology and thoracic surgery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Breath Diagnostics social profiles

Digital presence

Breath Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Breath Diagnostics leadership team

Management profile

Number of profiles

Profiles7 records

Breath Diagnostics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Breath Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Breath Diagnostics

What does Breath Diagnostics do?

Breath Diagnostics develops the OneBreath™ diagnostic platform, a non-invasive in vitro diagnostic that captures and analyzes volatile organic compounds (VOCs) from a single exhaled breath to detect lung cancer and other respiratory diseases. The platform uses a patented silicon microreactor with aminooxy chemistry to derivatize carbonyl VOCs into stable cationic adducts, followed by ultra-high-performance liquid chromatography-mass spectrometry (UHPLC-MS) analysis, achieving 94% sensitivity and 85% specificity across 800+ patients in clinical trials.

Is Breath Diagnostics a public or private company?

Breath Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Breath Diagnostics founded?

Breath Diagnostics was founded in 2015. It employs 1 to 10 people.

Where is Breath Diagnostics based?

Breath Diagnostics is headquartered in Louisville, United States, in the North America region.

How does Breath Diagnostics make money?

Two revenue lines are on record. OneBreath™ Diagnostic Tests are the primary driver. The others are platform Technology Licensing.

Who are Breath Diagnostics's main competitors?

Direct peers on record are Owlstone Medical and Menssana Research. Emerging players are Breathtec Biomedical and Noze (formerly ScentAware). Broad incumbents are Philips Respiratory, Thermo Fisher Scientific, Agilent Technologies and Hologic. Others are Waters Corporation and Cleveland Clinic (Lung Cancer Screening Program).

Does Breath Diagnostics have an API?

No public API is recorded for Breath Diagnostics.

What industry is Breath Diagnostics in?

Breath Diagnostics's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mugglehead MagazineFive technologies moving from science fiction to reality: A Mugglehead roundupThis Mugglehead roundup profiles five emerging technologies moving from concept toward clinical or commercial deployment, spanning healthcare diagnostics, remote surgery, and nuclear energy. The article covers home sleep diagnostics through Beacon Biosignals' acquisition of CleveMed, microvascular heart disease assessment via CoroFlow, breath-based lung cancer screening from Owlstone Medical and Breath Diagnostics, remote robotic surgery involving Intuitive Surgical, Medtronic, Johnson & Johnson, and MicroPort MedBot's Toumai system, and Deep Fission's below-ground small modular reactor design. Each technology targets longstanding limitations in current practice—whether expanding access, improving diagnostic accuracy, or reducing infrastructure costs—with varying stages of commercialization ranging from early research to FDA-authorized procedures already performed across continents.PR NewswireBreath Diagnostics, Inc. Receives FDA Breakthrough Device Designation for OneBreath™ Platform to Aid Pre-Operative Pneumonia Risk AssessmentBreath Diagnostics, Inc. received FDA Breakthrough Device Designation for its OneBreath™ breath-based diagnostic platform, intended to assess postoperative pneumonia risk in patients scheduled for elective cardiac surgery. The platform uses liquid chromatography-mass spectrometry to analyze volatile organic compounds from a single exhaled breath specimen, making it the first FDA-designated device to apply LC-MS-based molecular analysis to human breath. The company plans to leverage the Breakthrough Devices Program to advance OneBreath™ through its regulatory pathway, though the designation is based on preliminary data and does not guarantee FDA approval.Mugglehead MagazineMedical sector drives rising adoption of breath analyzers: Fortune Business InsightsThe global breath analysis technology market was valued at US$742.9 million in 2025 and is projected to reach US$1.33 billion by 2034, growing at a compound annual growth rate of 6.9%, driven by rising chronic disease prevalence and demand for non-invasive diagnostics. The medical diagnostics segment dominated the market in 2025, with innovations in sensor technologies enabling early disease detection through volatile organic compound analysis. North America led the market with US$291.6 million in value, while companies like Breath Diagnostics have developed patented systems such as OneBreath that detect lung cancer with 94% sensitivity.Mugglehead MagazinePrestigious medtech intelligence firm recognizes Breath Diagnostics for innovationLife Science Intelligence, a medtech research firm, recognized Breath Diagnostics in its 2025 Emerging Innovators Report for its non-invasive OneBreath lung cancer breath test, placing the company among over 500 innovators from 36 countries. Breath Diagnostics is currently fundraising toward a $3 million goal (almost 30% achieved) and recently installed a mass spectrometry system from Waters Corp to enhance its screening technology, which demonstrated 94% sensitivity and 85% specificity in clinical trials involving over 800 patients. The company is working toward developing a CLIA laboratory developed test and pursuing FDA approval, with the U.S. addressable market for lung cancer screening estimated at over $63 billion.Mugglehead MagazineBreath Diagnostics completes install of advanced mass spectrometry systemBreath Diagnostics, a lung cancer breath screening company, installed an advanced mass spectrometry system from Waters Corp in its laboratory. The new system enhances detection sensitivity, data quality, and reproducibility for breath analysis.Mugglehead MagazineUniversity of Texas develops lung cancer breath analysis systemResearchers from the University of Texas at Dallas have developed an electrochemical biosensor with artificial intelligence capable of analyzing breath samples to detect lung and thoracic cancers, identifying eight volatile organic compound biomarkers with 90% accuracy in a study of 67 patients. The technology, published in the peer-reviewed journal Sensing and Bio-Sensing Research, represents a potentially non-invasive and affordable screening tool that could eventually be incorporated into routine physical examinations. Breath Diagnostics, an American company with a competing OneBreath system tested in over 800 patients achieving 94% sensitivity, was cited as a more advanced benchmark in the field.American City Business JournalsBreath Diagnostics nears market launch for OneBreath deviceBreath Diagnostics is preparing to launch its OneBreath device for predicting pneumonia, aiming to complete FDA trials by next calendar year. The company also plans to conduct an initial public offering within six months after raising approximately $8 million and currently seeking an additional $3 million through Regulation CF.PR NewswireBreath Diagnostics Technology Demonstrates Breakthrough in Predicting Pneumonia Through Exhaled Breath AnalysisBreath Diagnostics announced results from a peer-reviewed clinical study showing its OneBreath™ breath analysis technology can both diagnose and predict pneumonia in cardiac surgery patients, achieving an AUROC of 0.833 and PRAUC of 0.818 in a prospective study of 75 patients. The predictive model identified high-risk patients days before clinical symptoms emerged using only preoperative breath samples, representing one of the first demonstrations that exhaled breath volatile organic compounds can reliably serve as biomarkers for future disease. The company plans to expand validation into larger multi-center cohorts and pursue regulatory clearances in the United States and select international markets.Mugglehead MagazineInternational lung cancer screening market poised for steady growth: 2025 reportThe Business Research Company reports that the global lung cancer diagnostics and screening market is projected to grow by 9.6% annually, reaching a valuation of US$3.7 billion by 2029. This expansion is driven by rising incidence rates, early detection initiatives, and technological advancements such as liquid biopsies and breath analysis tools. Major industry players like AstraZeneca, Roche, and Bristol-Myers Squibb are developing new diagnostic technologies alongside smaller innovators like Breath Diagnostics.PR NewswireBreath Diagnostics Inc. Appoints Aaron Roebuck as President and Closes FinancingBreath Diagnostics Inc. announced the appointment of Aaron Roebuck as President, who brings nearly 30 years of experience in respiratory and cardiopulmonary medicine, most recently serving as Senior Director of Clinical Sciences at Vero Biotech. The company also closed a $1 million convertible note financing led by strategic investors, including CEO Ivan Lo, with funds allocated to general operations and R&D for the OneBreath™ platform. The OneBreath™ system is a non-invasive breath analysis technology in development for early detection of diseases such as lung cancer and pneumonia.